Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The PART study, a feasibility study comparing radical prostatectomy (RP) and partial ablation (PA) using HIFU of the prostate in men with unilateral, intermediate risk prostate cancer has now completed recruitment.

PART logo

The primary objective of the study was to assess the feasibility of randomising men to a trial of HIFU versus RP with a recruitment target of 80 men. In total, 87 men consented to join the PART study, and 82 of these men went onto be randomised. Patients will be followed up for a total of 3 years as per protocol, with the final follow-up expected to take place in May 2020. The PART research team now plan to submit an application to undertake the main, larger RCT comparing clinical, cost-effectiveness, and quality of life outcomes between radical treatments and PA. 

Similar stories

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.

FUTURE-GB looking ahead to 2022

FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.